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A health economic analysis was performed to assess the economic impact on the national
health care budget of using oral nutritional supplements (ONS), being a food for special
medical purposes also known as medical nutrition, for the treatment of disease related
malnutrition (DRM) in the community in the Netherlands. An economic model was devel-
oped to calculate the budget impact of using ONS in community dwelling elderly (>5 years)
with DRM in the Netherlands. The model reﬂects the costs of DRM and the cost reduc-
tions resulting from improvement in DRM due to treatment with ONS. Using ONS for the
treatment of DRM in community dwelling elderly, leads to a total annual cost savings of
C 13 million (18.9% savings), when all eligible patients are treated. The additional costs
of ONS (C 57 million) are more than balanced by a reduction of other health care costs,
e.g., re-/hospitalization (C 70 million). Sensitivity analyses were performed on all parame-
ters, including duration of treatment with ONS and the prevalence of DRM. This budget
impact analysis shows that the use of ONS for treatment of DRM in elderly patients in the
community may lead to cost savings in the Netherlands.
Keywords: disease related malnutrition, medical nutrition, oral nutritional supplements, economic impact, budget
impact, costs
INTRODUCTION
Malnutrition is a prevalent problem, which is known for many
years and is deﬁned as a state of nutrition in which a deﬁciency,
excess (or imbalance) of energy,protein,andother nutrients causes
measurable adverse effects on tissue/body form (body shape, size,
and composition) and function, and clinical outcome (Stratton
et al., 2003).Malnutrition thus includes both over-nutrition (over-
weight and obesity) and under-nutrition (insufﬁcient nutrition).
For the purposes of this article the term malnutrition is used only
for under-nutrition in health care, which is caused by changes of
the body metabolism due to acute or chronic diseases and/or treat-
ment interventions, which increases the daily nutritional needs,
also known as disease related malnutrition (DRM). Due to lack
of adequate nutrition because of this increased nutritional need,
an individual may move from a good nutritional status to frank
DRM in a matter of weeks, months, or years. The key factor in
the development of DRM is a nutritional intake that is insufﬁcient
to meet the increased nutritional requirements. DRM adversely
impacts on every organ system in the body with potentially seri-
ous consequences on a physical and psycho-social level that in turn
contribute to increased morbidity and mortality (Elia and Russell,
2009).
Abbreviations: DRM, disease related malnutrition; FSMP, food for special medical
purposes; iMTA Institute for Medical Technology Assessment B. V. (iMTA) of the
Erasmus University Rotterdam; ONS, oral nutritional supplements
As a consequence, treatment should be focused not only on the
underlying disease but also on the nutritional status.
Disease related malnutrition is highly prevalent in Europe, as
about 20 million patients are affected by DRM, costing EU gov-
ernments up to C 120 billion annually (Ljungqvist and de Man,
2009; Ljungqvist et al., 2010). DRM affects many people across
all healthcare settings, from older people living in the community
to patients in the hospital with speciﬁc conditions. A comparison
of the results of the measurement of DRM in the Netherlands,
Austria, Switzerland, New Zealand, and Germany show that about
25% of hospitalized patients and patients in care homes are mal-
nourished (Halfens et al., 2011). European studies regarding the
community dwelling elderly, report a prevalence of DRM ranging
from 19% in Russia up to 84% in Ireland (Stratton et al., 2003;
Gurina et al., 2011).
In the Netherlands about 50% of the patients in all healthcare
settings are at risk of DRM and 25% are actually malnourished
(Halfens et al., 2009). Comparing prevalence rates in different
countries and settings thus reveals that DRM in general is com-
mon, but that there is considerable ﬂuctuation due to no uni-
versally accepted deﬁnition of malnutrition and screening tools
for DRM.
As mentioned, DRM is common across a variety of patient and
age groups, but older people are particularly at risk; a large-scale
survey showed that the risk is 40% greater in people aged over
65 years, than in people under 65 years (Russell and Elia, 2009).
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With an aging population DRM continues to be a major public
health concern.
The consequences of DRM, if left untreated, are serious:
increased complication rates, morbidity, mortality, hospital read-
missions, and length of hospital stay (Elia et al., 2005; Sorensen
et al., 2008). These consequences result in an increased use of
healthcare resources (extra physicians’ visits, extended length of
stay in hospitals, extra costs in care homes, etc., Martyn et al.,
1998). In 2007 a cost of illness study was performed in the Nether-
lands by the Institute for Medical Technology Assessment B. V.
(iMTA) of the Erasmus University Rotterdam. This study reports
that the additional costs of DRM in the Netherlands are C 1.7 bil-
lion in 2006, which equals 2.8% of the total Dutch national health
expenditures at that time (see Costs of DRM).
Patients with DRM are often not able to meet the increased
nutritional requirements with their daily food due to a number
of different reasons related to disease and disability, impacting on
food intake, losses of nutrients, and/or increased requirements.
Although in some cases improvement of the quality or quantity
of food supplied can ameliorate the problem, in many cases the
person concerned is simply unable or unwilling to consume suf-
ﬁcient normal food to meet their requirements to manage the
DRM. In this case, it is vital to consider other options to improve
nutritional intake, such as enteral nutritional support. The term
enteral nutrition, also known as medical nutrition, comprises all
forms of nutritional support that imply the use “dietary foods
for special medical purposes (FSMP)” as deﬁned by the Euro-
pean Commission Directive 1999/21/EC independent of the route
of application. It includes oral nutritional supplements (ONS) as
well as tube feeding via nasogastric, nasoenteral, or percutaneous
tubes (Lochs et al., 2006). Meta-analyses on treatment of DRM
with medical nutrition show a reduction in mortality and compli-
cations (e.g., sepsis,wound care, andpneumonia), improvement of
wound healing, and an increase of Quality of Life (Elia et al., 2005;
Stratton et al., 2005; Sneller beter, 2008). Stratton and Elia (2007)
concluded that enteral nutritional support can be an important
part of the management of any patient.
The published literature (meta-analyses and systematic
reviews) provides evidence that ONS, being a food FSMP, are an
effective treatment for patients with DRM:
• Mortality rates are signiﬁcantly lower (odds ratio of 0.61; 95%
CI 0.48–0.78; Stratton et al., 2003). Meta-analyses consistently
show a reduction in mortality, e.g., a 24% reduction (Stratton
et al., 2003),particularly in undernourished older people (Milne
et al., 2005, 2006, 2009).
• Complication rates, including infections, are signiﬁcantly
reduced (odds ratio of 0.31; 95% CI 0.17–0.56; Stratton et al.,
2003; Stratton and Elia, 2007). Another systematic review
showed that medical nutrition can signiﬁcantly reduce the risk
(25% risk reduction) of developing pressure ulcers (Stratton
et al., 2005).
• ONS have been demonstrated to be more effective than dietary
advice and snacks (Stratton et al., 2006; Stratton and Elia, 2007).
• Potential cost savings as a result of reduced healthcare use can be
realized in both the hospital and the community setting (NICE,
2006). A previous Dutch health economic analysis by our group
showed that the use of ONS for treating patients in the hospital
setting would lead to an annual cost saving of C 40.4 million
per year in the Netherlands (Freijer and Nuijten, 2010).
In summary, DRM is common and may be costly, if left
untreated. Therefore the objective of this study is to assess the
economic beneﬁt for the society in the Netherlands when commu-
nity dwelling elderly (>65 years) patients with DRM are treated
with ONS.
MATERIALS AND METHODS
HEALTH ECONOMIC MODELING – MODEL DESIGN
A health economic model was constructed using decision ana-
lytical techniques (Weinstein et al., 1980). The model calculates
the budget impact of using ONS in patients who are eligible (see
Study Population: Type of Patients, Type of Intervention, and
Comparator, The Total Number of Patients, and Prevalence of
Disease Related Malnutrition) for ONS due to DRM. The model
allows the assessment of the cost savings resulting from improve-
ment in DRM due to treatment with ONS. Clinical probabilities
and resource utilization were based on clinical trials and published
literature (see Re-/Hospitalization); cost data were derived from
ofﬁcial price tariffs.
Figure 1 shows the structure of the model for treatment with
ONS. The ﬁrst branch point in a tree is called a decision node
because it corresponds to a choice of treatment – ONS or “no
ONS” – in patients eligible for ONS due to DRM. A decision node
is represented as a small square (). Subsequent to the decision
node, the structure of the decision tree is shown,which is identical
for both treatment options. Theother branchpoints indicate prob-
abilities. DRM status may improve (reduction of malnutrition), or
may deteriorate or remain similar (no reduction of malnutrition).
Data sources used included published literature, clinical trials,
ofﬁcial Dutch price/tariff lists, and national population statistics.
Tobe able to test the robustness of the outcomes of themodel to the
variance in the input values, a sensitivity analysis was performed.A
sensitivity analysis is a technique for systematically changing vari-
ables in a model to determine the effects of such changes (Saltelli
et al., 2008). Our univariate sensitivity analyses (a single variable
and its attributes of the applicable major entity that is being ana-
lyzed in the study) were based on the modiﬁcation of the basic
clinical and economic assumptions in the model. This procedure
entails changing one of the model parameters through a range of
plausible values and assessing the effect on the overall outcome of
the analysis.
STUDY POPULATION: TYPE OF PATIENTS, TYPE OF INTERVENTION, AND
COMPARATOR
The study population is based on a comparison of the use of ONS
versus “no use” of ONS due to DRM in elderly patients of 65 years
and over (>65 years) in the community setting. ONS is the inter-
vention and “no use” of ONS is the comparator, meaning that
this group of patients with DRM is getting the standard care (e.g.,
their normal daily food as usual without any special nutritional
intervention like ONS). This study population is the most studied
and common in clinical trials regarding ONS. To be able to calcu-
late the budget impact of the use of ONS, an incremental costing
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FIGURE 1 | Model to calculate the budget impact of the use of ONS; a linear decisionTree.
approach was used (see Cost Assessment). The incremental cost
difference was based on the costs associated with the cost of ONS
and the cost of illness of DRM. All health care costs other than use
of ONS and costs of DRM are not included in the model.
The rational for selecting elderly patients is that aging will have
an increasing impact on the Dutch healthcare budget. Maintain-
ing an adequate functional status in older people is considered a
high priority by the World Health Organization to help prevent
disability and institutionalization (WHO, 2002). Institutionaliza-
tion generally means high health care costs, especially in hospitals,
which was also shown by the cost of illness analysis for DRM in
the Netherlands (see Costs of DRM). Preventing hospitalization
or decreasing the duration of hospitalization will therefore most
probably lead to cost savings. The cost savings due to a reduction of
hospital length of stay by treating patients withONS in theNether-
lands has recently been published (Freijer and Nuijten, 2010).
The focus of this analysis is on the use of ONS in the community
setting. Within the national health care system in the Netherlands,
the costs of treatments in the community considerably affect the
total health care budget. In 2005, about 6% of the population
older than 30 years received publicly ﬁnanced nursing and care,
two thirds received some form of home care and one third lived
in a home. The sector nursing and residential care spent nearly C
10 billion of the total public spending in that year, which is ∼2%
of gross domestic product in the Netherlands. Spending on public
nursing care between2005 and2030 is expected to increase by3.4%
per annum. This is faster than the growth in the number of users
(1.2%) and a result of rising health care costs and increasing health
care needs (Woittiez et al., 2009). Therefore interventions used to
manage DRM in the community setting in the Netherlands, may
have a major impact on the national health care budget. Patients
living at home, who may, or may not be assisted by home care and
patients living in residential homes, are considered community
dwelling patients (Schols et al., 2004). Dutch home care services
deliver care and nursing to patients living at home. This involves
general and special nursing,household care andpersonal care. Res-
idential homes offers assisted living (a save living environment) to
older people who are still able to do a considerable part of their
daily activities themselves. The perspective of this study is that
of the compartment of patients living at home with assistance of
home care (“thuiszorg” in Dutch) and patients living in residential
homes (“verzorgingshuis” in Dutch) being the community setting.
COST ASSESSMENT
An incremental costing approach was used: all drug utilization
(and other health care utilization), being similar between the two
treatment arms, is not included in themodel. The incremental cost
difference was based on the costs associated with the cost of ONS
and the cost of illness of DRM. The model is based on the assump-
tion that the use of ONS only has an impact on re-/hospitalization
due to DRM.
The perspective of the study was a limited societal perspective,
because indirect costs due to productivity loss were not included,
as the study population concerns elderly people, most likely to be
retired. Discounting of costs and effectiveness measures was not
performed, because the time horizon of the model did not exceed
1 year.
DATA
The Total Number of Patients
The Dutch Central Buro for Statistics (CBS) reports that the total
number of elderly patients (>65 years) in home care in theNether-
lands was 499,700 in 2004 (CBS, 2006). As no data were available
for 2009, the increase from 119,000 in ﬁve previous years was
extrapolated to the subsequent 5 years giving a ﬁgure of 620,000
in 2009 using CBS (2006) data. There are 100,223 persons living in
residential homes in the Netherlands (Actiz, 2009). As these data
do not indicate the proportion of patients older than 65 years, we
made the assumption that 100% is 65 years or older. The analysis
is therefore based on a total number of 720,223 patients in 2009.
Prevalence of Disease Related Malnutrition
In the Netherlands the department of Health Care and Nursing
Science of the University of Maastricht is performing an annual
national independent measurement of health care problems. Since
2004 this annual Dutch National Prevalence Measurement of Care
Problems (LPZ) includes also an audit on DRM. The report of
2009 shows that one out of two patients in the Dutch health care
system is at risk of DRM and 25% is malnourished. In home care
and care homes the prevalence of DRM is somewhat lower but
the prevalence of DRM is still 20% with a mean age of the pop-
ulation of 77 years (Halfens et al., 2009). The base case analysis is
based on data from this Dutch report, which provides a prevalence
of 20% of DRM in elderly (>65 years) living in the community
setting.
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Re-/hospitalization
A number of studies have been done in the community setting, but
only a few have incorporated end-points which are amenable to
economic modeling. Nevertheless, three studies in the community
have shown that ONS result in a reduction in re-/hospitalization
(Gariballa et al., 2006;Norman et al., 2008a;Chapman et al., 2009).
Re-/hospitalization is a key driver of costs and is one of the con-
sequences of DRM (Martyn et al., 1998; Elia et al., 2005; Sorensen
et al., 2008) when left untreated. To be able to calculate the bud-
get impact of ONS for malnutrition in the community setting, we
used the re-/hospitalization data as indication for the impact of
ONS on DRM due to lack of other amenable data. For each study
we calculated the probability of re/hospitalization (Table 1) which
was then used as a measure for the reduction of DRM; for our eco-
nomic analysis, a probability of 0.72 means that DRM is reduced
by 27%.
The study by Gariballa tested whether ONS for older patients
(>65 years) during acute illness leads to a clinical beneﬁt. This
study provided a reduction of re-/hospitalization from 40 to
29% over a period of 6months (Gariballa et al., 2006). In
another study by Chapman, ONS was tested in community
dwelling undernourished elderly alone or in combination with
a hormonal supplement. Fewer patients needed hospitalization
in the group, which received only the ONS (38.5%) versus the
group which received the no (=standard) treatment (69%; Chap-
man et al., 2009). Norman studied the effect of ONS (inter-
vention group) versus no ONS (control group) in malnour-
ished patients after hospital discharge for 3months. Non-elective
readmissions were higher in the control group than in the
intervention group (48 and 26% respectively; Norman et al.,
2008a).
For clinical outcomes, the general rule may be to assume that
data are not country-speciﬁc (Nuijten, 1998). Re-/hospitalization
is considered a clinical outcome. Therefore the international data
on re-/hospitalization were used in this analysis for a Dutch health
economic evaluation of ONS in elderly patients (>65 years) in the
community setting.
The base case analysis was based on a rather conservative
reduction of DRM of 25% based on the most conservative prob-
ability of reduction in re-/hospitalization shown in the described
international studies (Table 1).
Recommended amount of intake, duration, and type of ONS
The typical prescription for ONS is two bottles (2ml × 200ml)
per day per patient. The studied duration of time using ONS
varies from 6weeks (Gariballa et al., 2006) to 1 year (Chapman
et al., 2009). In the study by Norman the duration of ONS was
Table 1 | Results of international studies and meta-analysis on
probability of re-/hospitalization of ONS.
Re- hospitalization With
ONS (%)
Without
ONS (%)
Difference
(%)
Probability
Gariballa et al. (2006) 29 40 11 0.72
Chapman et al. (2009) 38 69 31 0.55
Norman et al. (2008a) 26 48 22 0.54
3months (Norman et al., 2008a). International recommendations
for patients who are identiﬁed as malnourished on screening, state
that monitoring should be in place monthly to every 2–3months
with a maximum of monitoring for three to 6months by health-
care professionals with the relevant skills and training1,2. The base
case analysis was based on the most realistic and conservative
period of 3months.
The Dutch Guidelines for the treatment of DRM describe the
nutritional need for patients with DRM, including the use of
ONS (Stuurgroep Ondervoeding, 2011). The type of this nutri-
tion intervention depends on several facts, like the nutritional
intake with the daily food, which differs per patient. For our
analysis we used the price of the most used ONS product (a
“standard”ONS), containing energy (1.5 kcal/ml) and all the basic
nutrients like protein carbohydrates, fat, ﬁbers, and vitamins and
minerals.
Costs of DRM
In 2007 a rough estimate was made for the disease related costs
of malnutrition in the Netherlands by a university-based scien-
tiﬁc institute that is distinguished by independent research in
medical technology assessment, including health economics and
health outcomes research and dedicated to support the use of cost–
effectiveness information in healthcare decision making (Institute
for Medical Technology Assessment B.V. – iMTA, Erasmus Uni-
versity, Rotterdam,The Netherlands). The total additional costs of
DRM in the total care sector were estimated at C 1.7 billion for
2006 which equals 2.8% of the total Dutch national health expen-
diture and 5.8%of the total costs of the healthcare sectors analyzed
in the report (hospital-, nursing home-, residential home-, and
home care setting) at that time (Van der Heijden et al., 2009). The
total costs of DRM were analyzed separately according to gender
(men and women), age (“18< age< 60” and “age> 60”), health-
care sector (hospital-, nursing home-, care home-, and home care
setting), and disease. To be able to take into account the effects
of aging, because especially old people use a lot of care, analy-
ses were made for an age group of patients older than 18 and
younger than 60 years of age and for the group of 60 years and
older. About 50% of the total expenditure on DRM was attrib-
utable to the hospital setting (C 830 million). The proportions
for the nursing home- (C 352 million), residential home- (C 305
million), and home care setting (C 196 million) accounted for 21,
18, and 12% respectively. The calculations were based on the total
costs per illness category, national prevalence data on DRM and a
weighting factor for the extra costs of care for patients with DRM
versus patients with no DRM. The total costs of care per illness
category were based on the data of the Dutch National Institute
for Public Health and the Environment (RIVM) from 2003, which
were indexed to 2006 (Slobbe et al., 2006). The national prevalence
data on DRM were taken from the LPZ of that year (Meijers et al.,
2006) and the weighting factor was based on a Dutch study which
showed that the length of stay for patients with DRM was longer
(30%) than for patients without DRM (Kruizenga et al., 2005).
For home care, residential-, and nursing home care, international
1www.bapen.org.uk
2www.NICE.org.uk
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studies have shown a signiﬁcantly increased use of healthcare
resources and costs by patients identiﬁed as malnourished or at
risk of malnutrition compared with non-malnourished patients
(Stratton et al., 2003; Müller et al., 2007; Norman et al., 2008b;
Banks et al., 2010; Cawood et al., 2010a). As concrete ﬁgures of
the increase use of healthcare resources in these settings in the
Netherlands are lacking, the same weight factor of 1.3 for these
non-hospital sectors was used.
Moreover, this weighting factor of 1.3 was comparable with
those used for the estimations of the costs of DRM in the United
Kingdom and in Germany (1.3 and 1.4 respectively; Elia et al.,
2005; Pirlich et al., 2006). For our current analysis, we used this
iMTA report and indexed the costs of DRM per illness category to
2009, using the inﬂation index rate from CBS, Statistics Nether-
lands. We only did this indexing for the group of patients aged
60 years of age and older (elderly) in the settings residential-
and home care, as these settings are community settings in the
Netherlands (Table 2).
Costs of Treatment
The price of a standard bottle ONS is C 2.20, which corresponds
with the list price in 2009 as registered in the Dutch market.
The costs for a hospital are lower due to discounts. The costs
for a patient at the pharmacy are higher due to a mark-up for
the pharmacist and VAT. Therefore the most realistic price for
a bottle would be C 2.37, including VAT, which is used in the
analysis.
Table 2 | Costs of DRM in elderly (>60years) per illness category in
community in the Netherlands in 2009 (million Euros)*.
Illness category Residential home Home care Total
Infectious diseases 720.000 1.160.000 1.880.000
Cancer 1.816.765 16.083.713 17.900.478
Endocrinology 971.757 3.215.000 4.186.757
Diabetes 1.228.387 3.215.000 4.443.387
Hematology 230.000 1.520.000 1.750.000
Psychiatry 83.775.896 11.047.385 94.823.280
Neurology 997.523 4.782.222 5.779.745
Dementia 1.394.273 10.294.199 11.688.472
Spinal cord injury 1.193.333 7.173.333 8.366.667
Eye/ear 0 0 0
Cardiovascular 10.206.524 15.590.556 25.797.080
CVA, hemiparesis 13.288.667 16.026.517 29.315.184
Respiratory 3.709.924 8.221.544 11.931.468
Gastro-intestinal 913.889 7.731.331 8.645.220
Urogenital 904.896 0 904.896
Dermatology 436.739 2.446.434 2.883.173
Musculoskeletal 2.976.678 32.377.870 35.354.549
Congenital 0 0 0
Traumata – intoxications 4.849.538 5.143.498 9.993.036
Hip replacement 0 0 0
Total 109.730.125 146.028.603 275.643.390
*Based on cost of care per illness of the Dutch National Institute for Public Health
and the Environment (RIVM; Slobbe et al., 2006) indexed to 2009.
RESULTS
BASE CASE ANALYSIS
The base case analysis is based on the following values:
• Total number of patients: A total of 720,223 patients were used
for the base case analysis, based on national data (see The Total
Number of Patients; CBS, 2006; Actiz, 2009). The sensitivity
analysis is based on a range varying between plus and minus
10% of the total number of patients.
• Proportion of DRM: The base case analysis (20%) is based on
Dutch data regarding prevalence of DRM in the community
setting in the Netherlands (Halfens et al., 2009). The sensitivity
analysis is based on a range varying the base case value by plus
and minus 10% and plus and minus 20%. We tested two ranges
in order to assess the level of sensitivity of the outcomes of the
model to this parameter as this parameter is key driver of the
model.
• Duration and amount of intake of treatment with ONS: The
base case analysis is based on a mean duration of treatment
of 12weeks with 2ml× 200ml per day (see Recommended
Amount of Intake, Duration, and Type of ONS). A sensi-
tivity analysis is performed varying the duration from 2 to
4months.
• Reduction of DRM: the base case analysis was based on a rather
conservative reduction of DRM of 25% based on the most con-
servative probability of reduction in re-/hospitalization shown
in the described international studies (see Re-/Hospitalization).
The results of the base case analysis are shown in Table 3. This
analysis shows that the use of ONS for elderly with DRM in the
community setting does not lead to additional costs. In fact, the
use of ONS reduces the costs from C 275.643 to C 262.657 million
which corresponds with a total national cost saving of C 12.986
million (4.7% savings). The additional costs of ONS (C 57.335
million) are more than balanced by a reduction of the total costs
of DRM due to a reduction of re-/hospitalization. Therefore, the
use of ONS would lead to a positive annual budget impact of
nearly C 13 million when all eligible patients are treated, based on
the population of 720,223 patients living in the community setting
in the Netherlands in 2009.
SENSITIVITY ANALYSIS
The results of the sensitivity analyses are presented in Table 4. We
tested two ranges in the sensitivity analysis in order to assess the
sensitivity of the outcomes of the model to the key parameters in
the model. These results show that the use of ONS remains cost
saving compared with “no use” of ONS in nearly all sensitivity
Table 3 | Results of the base case analysis: budget impact of ONS
(without and with ONS) in elderly with DRM in the community in the
Netherlands in 2009 (million Euros).
Without ONS With ONS Savings
Costs of DRM C 275.643 C 205.322 C 70.321
Costs of ONS C 0 C 57.335 −C 57.335
Budget impact C 275.643 C 262.657 C 12.986
www.frontiersin.org May 2012 | Volume 3 | Article 78 | 5
Freijer et al. Budget impact of medical nutrition
Table 4 | Results of the base case* and the sensitivity analyses**
(million Euros).
Analysis Range*** Without
ONS
With
ONS
Savings
Base case C 276 C 263 C 13
Prevalence malnutrition −10% C 276 C 257 C 18
+10% C 276 C 268 C 7
−20% C 276 C 251 C 24
+20% C 276 C 274 C 1
Total number of patients −10% C 276 C 257 C 18
+10% C 276 C 268 C 7
Duration of treatment ONS −1month C 276 C 244 C 32
+1month C 276 C 282 −C 6
*The overall outcome of the budget impact analysis following the calculation
model for using ONS or not using ONS by elderly patients in the community.
**Checking the robustness (sensitivity) of the base case by changing one of the
model parameters through a range of plausible values.
***The values used in the base case are changed by a range of plausible values.
analyses. The budget impact is most sensitive to the duration of
treatment with ONS; the break even for the duration of treatment
is 3.7months.
DISCUSSION AND CONCLUSION
An analysis was performed to assess the economic impact of the
use of ONS in community dwelling elderly patients (>65 years)
with DRM, on the national health care budget in the Nether-
lands. The rational for performing this budget impact analysis
for the cohort of elderly patients in the community is that the
aging society in the Netherlands in the future will have a high
impact on the healthcare budget. Therefore interventions used
to manage DRM in the community setting in the Netherlands,
may have a major favorable impact on the national health care
budget, as the proportion of elderly will increase. Each year the
Dutch Ministry of Health has to decide which interventions will
be reimbursed and an budget impact calculation can provide valu-
able information for the decision making process. This budget
impact analysis shows that using ONS for the treatment of DRM
in community dwelling elderly leads to cost savings: additional
costs for ONS are offset by substantial cost savings and therefore
support the existing clinical guidelines also from an economic
point of view. In the UK, the British Association for Parenteral
and Enteral Nutrition (BAPEN) has used a similar approach to
inform their National Institute for Health and Clinical Excellence
(NICE) to support the guideline development and contribute to
the evidence base, as economic evaluations are included in their
guidance in order to recommend those treatments that represent
value for money. Their systematic analysis of the costs of DRM
in the UK and use of ONS in hospital and community settings
showed also some insights into the economic burden of malnu-
trition and the value of ONS in one healthcare system (Russell,
2007).
Recently other economic studies in the ﬁeld of DRM have been
performed for the UK by Guest et al. (2011) and Cawood et al.
(2010b) and for Germany by Norman et al. (2011). The study
of Guest et al. can be considered a cost of illness study as this
study gives a good overview of the current way malnourished
patients are treated in the community including the economic
impact, although the nutritional intervention was often inap-
propriate (vitamin and mineral supplements). Guest et al. also
show that only 23% of the malnourished patients are actually
treated with a nutritional intervention. The study by Cawood et
al. has yet only been published as an abstract, but the described
methods seem similar to our analysis. A big difference in both
budget impact analyses is the inclusion of the cost of patient
monitoring, which is one of the limitations of our study. The
study by Norman et al. is a cost utility analysis of ONS, in which
the cost–effectiveness of the improvement of quality of life has
been calculated in terms of quality adjusted life years (QALY).
Both studies provide important information on the economics
of DRM, but the UK study does not include the impact of ONS,
and the German study is limited to the patient-based level with-
out extrapolation to the economic impact at a population level.
As a consequence the results of these two studies are not compa-
rable with the results of our own economic analysis. In addition,
the two studies were performed outside the Netherlands, where
different treatment patterns and ﬁnancing systems may lead to
different costs.
One of the limitations of our study is that we did not include
all costs due to lack of data, e.g., the cost of patient monitoring
(assessment and follow up) for DRM.
Also due to lack of data on patients living at home without
assistance of home care, the perspective of this study is that of the
compartment of patients living at home with assistance of home
care. This may also be a limitation of this study.
The used duration of treatment with ONS may be another
limitation. Patients of 65 years and older with a range of chronic
diseases could be in need of ONS for a longer period of time
than 3months to recover from DRM. The treatment with ONS
could then lead to a cost–increase. The sensitivity analysis on the
duration of treatment though, showed that the outcome of the
model is rather robust to changes in treatment duration. Finally
we had to use indirect clinical data for calculating the direct
effect of ONS on DRM. As only data of the effect of ONS in the
community exist on re-/hospitalization, which is one of the con-
sequences of DRM (Martyn et al., 1998; Elia et al., 2005; Sorensen
et al., 2008), we used re-/hospitalization as the efﬁcacy measure
of ONS on DRM. The probability value on re-/hospitalization
we used in this analysis (0.75) has been conﬁrmed by a recent
meta-analysis on hospital re-/admission. This systematic review
and meta-analysis by Stratton et al. examined the effect of ONS
versus routine care (no ONS) on admissions/readmissions in the
community setting. The three studies we used as basis for our
analysis were part of the total amount of six studies used in
this meta-analysis. ONS signiﬁcantly reduced the proportion of
patients admitted or readmitted to hospital from 33 to 24% with
a probability of 0.73. When including only trials in the elderly
(mean age≥ 65 years), the result remained signiﬁcant [OR 0.63
(95% CI 0.45–0.88), p = 0.007; Stratton et al., 2011]. Implicitly
we also assumed that there is no difference in mortality, com-
plications and Quality of Life between the use of ONS versus
“no use” of ONS in malnourished elderly patients living in the
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community. This is a conservative assumption toward the use of
ONS, because studies in elderly have shown a reduction in mortal-
ity, complications and an improvement in Quality of Life (Milne
et al., 2005, 2006; Stratton et al., 2005; Chapman et al., 2009)
which are also consequences of DRM. But because of the fact that
these outcomes were not speciﬁc enough, we did not use these
data in our model. So the real economic beneﬁts for the use of
ONS may be in fact higher than was calculated with the current
data set.
Despite the limitations, we have shown that the use of ONS has
a positive impact on the national budget, because:
1) Total costs for treatment with ONS are not higher than a treat-
ment strategy without ONS: the additional costs for ONS are
more than balanced by a reduction of the health care costs due
to a reduction of the costs of DRM.
2) The analysis is based on similar clinical properties for both
treatment strategies with regards to mortality and com-
plications. However, the use of ONS is associated with a
higher effectiveness, as this treatment leads to a reduction of
DRM only.
Sensitivity analyses were performed and resulted in the fact
that the use of ONS in nearly all parameters remains cost saving
compared to “no use” of ONS. The budget impact is most sensi-
tive to the duration of treatment with ONS. Treating patients for
4months with 2ml× 200ml per day, the costs savings are lost.
The break even for using the ONS is 3.7months, meaning that at
that point the costs and the savings are equal.
In conclusion, this budget impact analysis for the use of ONS
in elderly patients (>65 years) with DRM living in the commu-
nity setting in the Netherlands showed that the use of ONS in this
group of patients may lead to a positive impact on the national
health care budget in the Netherlands.
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